权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

EphB/EphrinB signaling in Systemic Sclerosis

系统性硬化症中的 EphB/EphrinB 信号传导

基本信息

批准号：
10697360
负责人：
Patrice Mimche
金额：
$ 34.56万
依托单位：
UNIVERSITY OF UTAH
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-15 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10697360
关键词：
Agonist Animal Disease Models Attention Autoimmune Automobile Driving Binding Biochemical Pathway Biological Process Biology Biopsy Blood Vessels Cell membrane Cells Chronic Collagen Connective Tissue Diseases Cutaneous DNA Sequence Alteration Data Deposition Dermal Development Diffuse Disease Elasticity Embryonic Development Endothelial Cells Endothelium EphB2 Receptor Ephrins Event Exposure to Extracellular Matrix FDA approved Family Fibroblasts Fibrosis Formulation Functional disorder Future Genes Genetic Models Glycosylphosphatidylinositols Goals Human Immune Inflammation Inflammatory Injury Interleukin-1 beta Ligands Link Literature Mediating Medicine Membrane Membrane Potentials Mesenchymal Modeling Molecular Molecular Weight Morbidity - disease rate Mus Mutant Strains Mice Myofibroblast Organ Palliative Care Pathogenesis Pathologic Pathology Pathway interactions Patients Phosphotransferases Play Process Production Proliferating Receptor Protein-Tyrosine Kinases Research Role Scleroderma Signal Pathway Signal Transduction Signaling Molecule Site Skin Skin injury Symptoms Systemic Scleroderma Tail Testing Tissues Toll-like receptors Vascular Diseases Work angiogenesis cell injury cell motility chronic autoimmune disease combat cytokine drug-like compound extracellular fibrogenesis innovation mortality mouse model mutant novel novel therapeutic intervention pharmacologic prevent receptor recruit response skin fibrosis small molecule therapeutic target transdifferentiation wound healing

项目摘要

Project Summary This proposal identifies the EphB2 receptor tyrosine kinase and its cognate EphrinB ligands as potential therapeutic targets to prevent vascular damage and fibrosis associated with systemic sclerosis (SSc, also known as scleroderma). A hallmark of SSc is the progressive and overwhelming deposition of extracellular matrix components, especially collagen, to cause the skin to become fibrotic and lose its elasticity. This process is thought to be driven by the recruitment of immune cells to sites of tissue damage, providing an inflammatory microenvironment to enhance fibroblast-to-myofibroblast transitions that in SSc patients leads to pathological expansion of pro-fibrotic cells and massive upregulated expression of collagen and other genes involved in fibrosis. As the biochemical pathways that control these events remain incompletely described, we focused our attention on potential membrane-associated molecules that may help interpret extracellular signals and aid the conversion of dermal fibroblasts into fibrogenic myofibroblasts, and identified the EphB2 receptor interacting with its EphrinB ligands as possible important components. Emerging data support the involvement of EphB-EphrinB in fibrosis of multiple organs, including our previous work, however little is known about the potential role of these highly conserved signaling molecules in the pathogenesis of SSc. Using human skin biopsies and mouse models of skin fibrosis, we will test the hypothesis that upon chronic, immune-mediated skin injury, EphB2 expression becomes strongly upregulated and the enhanced signaling pathways activated by this molecule are critical for the transdifferentiation of quiescent dermal fibroblasts into fibrogenic myofibroblasts to help bring about skin fibrosis. Our general idea is that when bound to EphrinB ligands expressed on various cells of the injured skin microenvironment (including endothelial cells), activated EphB2- expressing fibroblasts will initiate a differentiation process leading to their transformation into pro-fibrotic myofibroblasts. In support of this, preliminary data is provided that shows EphB2 expression is highly upregulated in human skin from SSc patients and in normal human dermal fibroblasts exposed to the pro- fibrotic inflammatory cytokine TGF-β1, and that skin fibrosis can be modulated by disrupting EphB2 either through genetic mutation or novel pharmacological approaches. The preliminary data has guided the formulation of three Specific Aims that will further test our ideas. Aim 1 will determine whether activation of EphB2 forward signalling is required for the progression of skin fibrogenesis. Aim 2 will test the hypothesis that EphB2-EphrinB interactions and signaling contributes to vascular damage and defective angiogenesis in SSc. Finally, Aim 3 will determine whether therapeutic targeting of these molecules will mitigate skin fibrosis. The proposed research is highly significant and innovative as it will reveal a key molecular mechanism that drives excessive fibrosis in SSc, and will also provide important early data on how novel small molecules that target EphB2-EphrinB interactions and signaling could be employed as future therapies to treat SSc.

项目摘要该提议鉴定了EphB 2受体酪氨酸激酶及其同源EphrinB配体作为潜在的治疗靶点，以预防与系统性硬化症（SSc，也称为硬皮病）。SSc的一个标志是细胞外基质的进行性和压倒性沉积，基质成分，特别是胶原蛋白，导致皮肤纤维化并失去弹性。这这一过程被认为是由免疫细胞募集到组织损伤部位驱动的，炎症微环境增强SSc患者中成纤维细胞向肌成纤维细胞的转化，促纤维化细胞的病理性扩张以及胶原蛋白和其它基因的大量上调表达参与纤维化。由于控制这些事件的生化途径仍然没有完全描述，我们将我们的注意力集中在可能有助于解释细胞外信号的潜在膜相关分子上帮助真皮成纤维细胞转化为纤维化肌成纤维细胞，并鉴定了EphB 2受体作为可能的重要组分与其EphrinB配体相互作用。新兴数据支持参与 EphB-EphrinB在多个器官纤维化中的作用，包括我们以前的工作，但是关于EphB-EphrinB在多个器官纤维化中的作用知之甚少。这些高度保守的信号分子在SSc发病机制中的潜在作用。使用人类皮肤活检和皮肤纤维化的小鼠模型，我们将测试的假设，在慢性，免疫介导的皮肤损伤后，EphB 2表达强烈上调，增强的信号通路被激活对于静止的真皮成纤维细胞转分化为纤维化细胞是至关重要的肌成纤维细胞，以帮助带来皮肤纤维化。我们的总体想法是，当与EphrinB配体结合时，表达在受损皮肤微环境的各种细胞（包括内皮细胞）上，活化的EphB 2- 表达成纤维细胞将启动分化过程，导致它们转化为促纤维化细胞，肌成纤维细胞为了支持这一点，提供了初步数据，其显示EphB 2表达是高表达的。在来自SSc患者的人皮肤和暴露于前体的正常人真皮成纤维细胞中上调，纤维化炎性细胞因子TGF-β1，且皮肤纤维化可以通过破坏EphB 2或通过基因突变或新的药理学方法。初步数据已经指导了三个具体目标的制定将进一步检验我们的想法。目标1将决定是否激活 EphB 2正向信号传导是皮肤纤维化进展所必需的。目标2将检验以下假设： EphB 2-EphrinB相互作用和信号传导有助于SSc中的血管损伤和缺陷性血管生成。最后，目标3将确定这些分子的治疗靶向是否会减轻皮肤纤维化。的拟议的研究是非常重要和创新的，因为它将揭示一个关键的分子机制，驱动这也将提供重要的早期数据，说明靶向 EphB 2-EphrinB相互作用和信号传导可以用作治疗SSc的未来疗法。